Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 216Stomach Neoplasms 166Rectal Neoplasms 146Pancreatic Neoplasms 81Colonic Neoplasms 77Neoplasm Metastasis 67Esophageal Neoplasms 55Neoplasms 31Adenocarcinoma Of Esophagus 29Cholangiocarcinoma 28Carcinoma, Hepatocellular 26Adenocarcinoma 26Biliary Tract Neoplasms 23Lymphoma, Large B-Cell, Diffuse 19Recurrence 17Carcinoma, Non-Small-Cell Lung 16Gallbladder Neoplasms 14Breast Neoplasms 14Head and Neck Neoplasms 11Locally Advanced Rectal Cancer 10Liver Neoplasms 10Gastrointestinal Neoplasms 10Esophageal Squamous Cell Carcinoma 9Peritoneal Neoplasms 8Ovarian Neoplasms 8Colorectal Cancer Metastatic 7Bile Duct Neoplasms 6Urinary Bladder Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Extranodal NK-T-Cell 5

Interventions

tislelizumab 2Oxaliplatin 2tremelimumab 1olaparib 1durvalumab 1apatinib 1Tegafur 1Dacarbazine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Immunotherapy × Oxaliplatin × Clear all
NCT05223088 2025-03-18

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Fujian Cancer Hospital

Phase 2 Completed
40 enrolled
Gastrointestinal

Immunotherapy

NCT05479240 2023-06-18

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Not yet recruiting
94 enrolled

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡